After GLP-1: Demand Is Up, Budgets Are Down

What is the signal?

According to Kline + Company's 2026 Aesthetic Skin Care Consumer Insights survey, more than one-third of aesthetic consumers — 34% — report currently using GLP-1 medications. Their spending did not move one way. In the same survey, 28% of those users reduced non-surgical aesthetic treatments to afford the medication, and 20% reduced skin care spending and switched to less expensive skin care alternatives.

Yet another column in the same group grew. Of GLP-1 users, 19% increased spending on skin-tightening procedures and 13% increased spending on treatments designed to address volume loss. Kline frames this as medication often becoming a primary investment, which means every additional product or procedure must justify its place more clearly. The same survey found 87% of consumers say they are willing to pay more for clinically proven results.

Reporting gives the demand its shape. Seoul Economic Daily's English edition reports that users who lost weight rapidly on drugs such as Wegovy and Mounjaro report facial volume loss, sagging skin and hair loss, and that lines aimed at them are already appearing. Dr. Few Skincare released a range for the aesthetic needs of clients undergoing GLP-1 treatment or significant weight loss. The same article cites Vogue arguing the category could extend into body care, hair care and beauty devices.

The ingredient side has moved too. In BeautyMatter's coverage of ingredient trends at in-cosmetics Global 2026, proposals aimed at skin changes after rapid weight loss recurred. SC Labs showed a tightening blend intended to restore skin elasticity lost due to GLP-1 diets, Provital presented Intensilk as an active blend targeting fat metabolism, tissue architecture and caloric restriction mechanisms, and Akott Evolution pitched a reishi-based pairing aimed at 'Ozempic face' concerns.

Let me set the limits of this reading. The figures above — 34%, 28%, 20%, 19%, 13% and 87% — all come from one firm's consumer panel, and the population is aesthetic consumers rather than the general public, so they should not be widened to a whole market. Kline notes its physician-side survey is still in preparation, so there is no provider-level data. Usage figures also differ by source: BeautyMatter cites Circana reporting that 23% of households report GLP-1 usage, and elsewhere uses roughly one in eight US adults. Household and individual bases are mixed, so do not treat them as the same number. Supplier mechanisms and effects are the suppliers' own claims; what is recorded here is a signal about the ingredient market, not evidence of finished-product efficacy. This article was confirmed through searches narrowed to each source's own domain, because direct page fetching was blocked.

1. The same consumer cuts one column and grows another

The easiest mistake with this data is to summarise it as 'GLP-1 users spend less on beauty'. The numbers do not say that. What fell was everyday skin care and general non-surgical treatment; what rose was spending on elasticity and volume loss. A fixed outlay for medication appeared and the remaining budget was reallocated, rather than shrinking as a whole.

For product planning, that distinction comes before the price point. Aiming at the column that fell makes the contest 'the same function, cheaper', and the task becomes how far volume, packaging and formulation cost can come down. Aiming at the column that grew makes the contest a demonstration of why the spend is necessary, and cost shifts from raw materials towards evidence. The two columns are not a place one formula can occupy at once.

One more point. Kline's 87% is a response about paying more for clinically proven results. Consumers who cut spending did not give up on evidence. Even where a lower-priced line is chosen, this data does not support dropping to a product without support.

• Whether the target column — reduced everyday spend or increased corrective spend — is written in one line
• If the reduced column, whether the cost lever is set among volume, packaging or formulation
• If the increased column, whether the evidence (test items and duration) is set first
• Whether one product is being asked to win both columns

2. Name the skin condition, not the drug

In this category the most tempting word is the most hazardous. Putting a drug name or its nickname at the front of a claim suggests a cosmetic aiming at a medicinal effect, and markets handle that differently. A cosmetic is not a medicine, so treat drug-name claims as an item to verify in advance against labelling and advertising rules in each export market.

The alternative is not difficult. The demand is not a drug; it is a skin condition. What users described in the Seoul Economic Daily report was not a drug name but facial volume loss, sagging skin and hair loss. Scoping the product around a condition, such as skin after rapid weight change, lets the claim wording and the test design share one language.

A condition-based scope also widens the audience. Rapid weight change does not come only from medication. Covering everyone experiencing the same skin condition gives the product a longer life and keeps revenue from being tied to prescribing trends for one drug.

There is a limit to widening, too. Even a condition-based claim crosses out of cosmetics when it reads as reversing tissue structure. Let the strength of the wording be decided by the test results on hand.

• Whether a drug name or nickname appears in the product name, pack or advertising
• Whether the claim was rewritten around a skin condition rather than 'drug users'
• Whether claim strength sits inside the range of tests actually held
• Whether per-market advertising checks are on the planning schedule

3. Ingredient briefs already shifted to mechanisms

The notable part of the in-cosmetics Global 2026 coverage is not an individual ingredient but the shape of the brief. BeautyMatter reports that formulators are increasingly requesting hallmark-specific briefs rather than general anti-aging briefs, which favours suppliers able to back claims with data.

The GLP-1 proposals took the same shape. SC Labs' blend names elasticity lost on GLP-1 diets; Provital's Intensilk names fat metabolism, tissue architecture and caloric restriction. The offer is not 'an ingredient good for elasticity' but a split by which route the elasticity was lost.

For development, that reverses the order of ingredient selection. Normally a concept is set and ingredients are chosen to fit it. Under a mechanism-level brief, you first write one line on what caused the change you intend to address, then shortlist ingredients with data on that route. Elasticity lost to cumulative UV exposure and elasticity lost to rapid weight loss are not supported by the same evidence.

The practical constraint belongs in the same note. Most mechanism data suppliers present is ingredient-level testing. Those results cannot be transferred to a finished product's effect. Use ingredient data to choose the formulation direction, and build the evidence behind the claim again at finished-product level.

• Whether the cause — the route — of the change you address is written in one line
• Whether ingredients with data on that route were shortlisted first
• Whether ingredient-level and finished-product testing are separated in the brief
• Whether a line was drawn on how far supplier claims may enter your own claims

4. Hair moves on a different clock

Treating face and hair as one block in this category pulls the design out of shape. Reporting from Seoul Economic Daily on hair loss after rapid weight loss notes that the loss is real but typically temporary, with researchers pointing to telogen effluvium, a resting phase caused by rapid weight loss.

A temporary change means two things for the product. One is the period of use. A product used alongside recovery suits a volume and usage instruction built around a defined period better than a large size built for long-term use. The other is the level of the claim. Attaching language close to hair regrowth to a change that returns on its own puts the evidence and the wording out of step, and takes the product past what a cosmetic may address.

Realistically, the role a cosmetic can take in this column sits closer to the scalp environment and hair damage. During rapid weight change, diet and nutrition shift as well, so designing around what users actually feel — a dry or itchy scalp, hair breakage — is the workable route. That connection is a development hypothesis rather than a fact the sources above establish, so it has to be confirmed separately through sensory and irritation testing.

The same holds for body. If the category extends into body care as the Vogue citation suggests, enlarging a facial formula to cover more area is not the move. A larger application area resets dosage, fragrance strength, absorption speed and the dispensing rate of the pack.

• Whether face, hair and body are designed separately rather than as one formula
• Whether the usage period and volume assume a temporary change
• Whether hair claims stay within scalp environment and damage
• Whether dosage, fragrance and dispensing were recalculated when extending to body

5. What 'unfamiliar territory' in Korea means

In the Seoul Economic Daily report, a Korean beauty industry official described the market as still unfamiliar territory in Korea, while saying the industry is watching closely as the market grows. For a Korean brand that line reads two ways.

First, there is no domestic demand data yet. Every figure above comes from a US consumer survey. Setting quantities on the assumption of domestic sales would be planning without a basis. If you want to validate the category at home first, start with conservative quantities and scale after a response.

Second, exporting changes the picture. Demand has been observed in the US, and the product set is only now forming. What has to be decided then is not whether to enter but which column to enter. In the US it was treatment spending that grew and skin care spending that fell, so a cosmetic entering this space is better placed finding the room before, between and after procedures than claiming to replace them.

If you develop in Korea and ship abroad, look at the schedule as well. A new category takes longer on evidence and claim review than on formulation. Put test design and destination-market claim checks on the same line as formulation work from the start.

• Whether domestic and overseas demand evidence are kept separate in the brief
• Whether a domestic-first launch starts with conservative quantities
• Whether an export plan takes the space around procedures rather than replacing them
• Whether test design and claim review sit on the same schedule line as formulation

The first question for the brief

Instead of writing 'GLP-1 target', write the skin condition. One line such as 'loss of elasticity after rapid weight change' sets the user and the test items in the same sentence, and produces a claim that needs no drug name.

The second thing to write is the column. Choose one: does this product enter the column consumers cut, or the one they grew? If the cut column, the next line is how far volume, packaging and formulation cost can come down. If the grown column, the next line is which tests will build the evidence.

The last is scope. Decide now whether this is face only or extends to body and hair, and if it extends, record in the same cell what has to be recalculated for each — dosage, fragrance strength, dispensing rate, period of use. The most expensive mistake in this category is carrying a facial formula across unchanged.